During the last session, Sagimet Biosciences Inc (NASDAQ:SGMT)’s traded shares were 0.46 million, with the beta value of the company hitting 3.61. At the end of the trading day, the stock’s price was $3.14, reflecting an intraday loss of -4.27% or -$0.14. The 52-week high for the SGMT share is $20.71, that puts it down -559.55 from that peak though still a striking 32.17% gain since the share price plummeted to a 52-week low of $2.13. The company’s market capitalization is $101.11M, and the average intraday trading volume over the past 10 days was 0.68 million shares, and the average trade volume was 415.87K shares over the past three months.
Sagimet Biosciences Inc (SGMT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. SGMT has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Sagimet Biosciences Inc (SGMT) registered a -4.27% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.27% in intraday trading to $3.14, hitting a weekly high. The stock’s 5-day price performance is -15.59%, and it has moved by 1.95% in 30 days. Based on these gigs, the overall price performance for the year is -72.93%. The short interest in Sagimet Biosciences Inc (NASDAQ:SGMT) is 1.86 million shares and it means that shorts have 8.19 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 47.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, SGMT is trading at a discount of -91.08% off the target high and -91.08% off the low.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
Statistics show that Sagimet Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Sagimet Biosciences Inc (SGMT) shares have gone down -32.47% during the last six months, with a year-to-date growth rate more than the industry average at 41.35% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -17.10% this quarter and then jump 20.50% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -16.23%. While earnings are projected to return 44.74% in 2024.
SGMT Dividends
Sagimet Biosciences Inc is due to release its next quarterly earnings in October. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Sagimet Biosciences Inc insiders own 14.11% of total outstanding shares while institutional holders control 70.10%, with the float percentage being 81.61%.
